PCM
PGEN icon

Patient Capital Management’s Precigen PGEN Stock Holding History

Patient Capital Management’s Portfolio PGEN Stock Details PGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-450,000
Closed -$950K – 44
2022
Q1 		$950K Buy
+450,000
New +$1.1M 0.32% 43

Other funds holding PGEN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Diametric Capital Boston, Massachusetts $385M AUM 31.69% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Patient Capital Management's PGEN Position: Q1 2026 in Review

Patient Capital Management reduced its Precigen (PGEN) stake by 4.6% in Q1 2026, selling an estimated $3.51M and leaving 17,817,387 shares worth $69M. The position accounts for 2.52% of the portfolio, ranked #18.

Patient Capital Management first reported a position in PGEN in Q4 2021 and has held it in 18 quarters since. The position peaked at $87.1M in Q3 2025. 206 funds tracked by Wall St. Rank hold PGEN as of Q1 2026.

  • Patient Capital Management held 17,817,387 shares of Precigen worth $69M as of Q1 2026.
  • Patient Capital Management sold 856,079 Precigen shares in Q1 2026, an estimated $3.51M.
  • Precigen made up 2.52% of Patient Capital Management's portfolio in Q1 2026, its #18 holding.
  • Patient Capital Management first reported a position in Precigen in Q4 2021 and has held it in 18 quarters since.
  • Patient Capital Management's Precigen position peaked at $87.1M in Q3 2025.
  • 206 funds tracked by Wall St. Rank held Precigen as of Q1 2026.

Based on Patient Capital Management's 13F filing for Q1 2026, filed 14 May 2026.